


WHAT IS CLAIMED IS:

1. A PEG conjugate having the structure of the Formula

5



wherein


```
n is an integer between 1 and 10;
```

```
m is an integer between 1 and 10;
```

R is human growth hormone or methionyl human growth hormone.

2. The PEG conjugate of claim 1 having the structure

15



wherein R is human growth hormone or methionyl human growth hormone.

20

3. The conjugate of claim 2 wherein said human growth hormone comprises an amino acid sequence of SEQ ID NO:1.

5 4. The conjugate of claim 2 wherein said human growth hormone consists of an amino acid sequence of SEQ ID NO:1.

10 5. The human growth hormone-PEG conjugate of claim 3 or 4 wherein greater than 90% of said polyethylene glycol is conjugated to an amino-terminal phenylalanine of the amino acid sequence of SEQ ID NO:1.

15 6. The human growth hormone-PEG conjugate of claim 3 or 4 wherein greater than 95% of said polyethylene glycol is conjugated to an amino-terminal phenylalanine of the amino acid sequence of SEQ ID NO:1.

20

7. The human growth hormone-PEG conjugate of claim 5 wherein each mPEG has a molecular weight of about 20 kDa.

25 8. The human growth hormone-PEG conjugate of claim 6 wherein each mPEG has a molecular weight of about 20 kDa.

30 9. A composition comprising the human growth hormone-PEG conjugate of claim 7 and at least one pharmaceutically acceptable carrier.

35 10. A method of treating a patient having a growth or development disorder comprising administering to said patient a therapeutically

effective amount of the human growth hormone-PEG conjugate of claim 7.

11. The method of claim 10 wherein said growth
5 or development disorder is Growth Hormone Deficiency (GHD).

12. The method of claim 10 wherein said growth
or development disorder is Turner's syndrome.

10

13. The method of claim 10 wherein said growth
or development disorder is Chronic Renal
Insufficiency.

14. The method of claim 10 wherein said growth
15 or development disorder is small for gestational age (SGA).

15. A composition comprising the human growth
20 hormone-PEG conjugate of claim 8 and at least one
pharmaceutically acceptable carrier.

16. A method of treating a patient having a
growth or development disorder comprising
25 administering to said patient a therapeutically
effective amount of the human growth hormone-PEG
conjugate of claim 8.

17. The method of claim 16 wherein said growth
30 or development disorder is Growth Hormone Deficiency (GHD).

18. The method of claim 16 wherein said growth
or development disorder is Turner's syndrome.

35

19. The method of claim 16 wherein said growth or development disorder is Chronic Renal Insufficiency.

5 20. The method of claim 16 wherein said growth or development disorder is small for gestational age (SGA).